Get the Stockscreener App
468.94
0.66%
-3.12
United Therapeutics Corp stock is traded at $468.94, with a volume of 248.90K.
It is down -0.66% in the last 24 hours and down -8.13% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$472.06
Open:
$472.83
24h Volume:
248.90K
Relative Volume:
0.55
Market Cap:
$20.19B
Revenue:
$3.08B
Net Income/Loss:
$1.24B
P/E Ratio:
18.31
EPS:
25.6108
Net Cash Flow:
$1.07B
1W Performance:
+0.86%
1M Performance:
-8.13%
6M Performance:
+53.44%
1Y Performance:
+26.10%
1-Day Range:
$464.16
$474.99
1-Week Range:
$455.63
$474.99
52-Week Range:
$266.98
$519.99
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
468.94 | 20.33B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
124.05 | 54.82B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.29 | 50.36B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.46 | 46.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.81 | 36.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics appoints biomedical research leader to board By Investing.com - Investing.com Nigeria
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to Board of Directors, Effective January 21, 2026 - marketscreener.com
United Therapeutics appoints biomedical research leader to board - Investing.com
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors - United Therapeutics Investor Relations
Element Squared LLC Buys 5,027 Shares of United Therapeutics Corp (UTHR) - GuruFocus
Marquette Asset Management, LLC Buys 1 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corporation (UTHR): A Bull Case Theory - Finviz
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
Polaris Capital Management LLC Sells 5,600 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Reassessing United Therapeutics (UTHR) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension - TipRanks
United Therapeutics Corporation $UTHR Shares Sold by State of Alaska Department of Revenue - MarketBeat
SG Americas Securities LLC Purchases 7,483 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Position Decreased by Nepsis Inc. - MarketBeat
How United Therapeutics Corporation (UTH) stock expands through international marketsTreasury Yields & Verified Swing Trading Watchlists - Улправда
Is United Therapeutics Corporation stock a good choice for value investorsJuly 2025 Recap & AI Enhanced Execution Alerts - Улправда
MannKind Provides Business Updates and 2026 Growth Drivers - Benzinga
Robeco Institutional Asset Management B.V. Has $38.19 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) COO Sells $7,127,932.50 in Stock - MarketBeat
Director Jan Malcolm Sells Shares of United Therapeutics Corp - GuruFocus
United Therapeutics (UTHR): UBS Raises Price Target, Maintains B - GuruFocus
Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Performance Tethered To Its Attractive Financial Prospects? - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares - MarketBeat
United Therapeutics Corporation (UTHR) Stock Analysis: A Healthcare Giant with Strong Growth Potential and Robust Analyst Support - DirectorsTalk Interviews
Biotech developing organ transplant tech steps onto J.P. Morgan stage - Stock Titan
United Therapeutics Insider Sold Shares Worth $500,015, According to a Recent SEC Filing - marketscreener.com
United Therapeutics Corporation $UTHR Shares Bought by Merit Financial Group LLC - MarketBeat
Allspring Global Investments Holdings LLC Acquires 4,944 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics Corporation $UTHR Position Increased by Cwm LLC - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 137,900 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares - MarketBeat
United Therapeutics EVP & General Counsel Sells 11,000 Shares - TradingView — Track All Markets
United Therapeutics president sells $3.5m in stock - MSN
United Therapeutics Insider Sold Shares Worth $5,644,954, According to a Recent SEC Filing - marketscreener.com
Death Cross: Can United Therapeutics Corporation stock sustain market leadershipTrend Reversal & AI Based Buy/Sell Signal Reports - moha.gov.vn
Pacer Advisors Inc. Decreases Position in United Therapeutics Corporation $UTHR - MarketBeat
S&P 500 Futures Flat In Premarket Trading; United Therapeutics, Intel Lag - 富途牛牛
S&P 500 Futures Flat in Premarket Trading; United Therapeutics, Intel Lag - Barron's
United Therapeutics (NASDAQ:UTHR) Reaches New 1-Year HighHere's What Happened - MarketBeat
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
Jan Malcolm Sells 50 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Louis Sullivan Sells 5,950 Shares - MarketBeat
United Therapeutics Director Malcolm Jan Sells Shares - TradingView — Track All Markets
Voya Investment Management LLC Lowers Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Wedge Capital Management L L P NC Reduces Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR): Revisiting Valuation After Xenotransplantation Progress and Strong Financial Performance - simplywall.st
Will United Therapeutics Corporation (UTH) stock see valuation expansionJuly 2025 Earnings & Safe Capital Allocation Plans - Улправда
VIX Spike: Will United Therapeutics Corporation (UTH) stock see valuation expansionQuarterly Investment Review & Growth-Oriented Investment Plans - Улправда
Chmn Rothblatt Files To Sell 2,000 Of United Therapeutics Corp [UTHR] - TradingView — Track All Markets
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):